People · Operator

Joerge Klaube

Named in public records as an officer, director or promoter · active 2014–2014 · Biotechnology

1
Companies
1
Filings
$9.6M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Turnpoint Medical Devices, Inc.BiotechnologySeries A$9.6M$3.6M2014
Operator network

Joerge Klaube at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

George Boyajian · 3 companies · 1 sharedGeorge BoyajianJoerg Klaube · 3 companies · 1 sharedJoerg KlaubeChristopher York · 2 companies · 1 sharedChristopher YorkJerry C. Ruddle · 2 companies · 1 sharedJerry C. RuddleJoerg H. Klaube · 2 companies · 1 sharedJoerg H. KlaubeChristopher J. York · 1 companies · 1 sharedChristopher J. Yo…Douglas C. Hulse · 1 companies · 1 sharedDouglas C. HulseDouglas Hulse · 1 companies · 1 sharedDouglas HulseDouglas J. Hulse · 1 companies · 1 sharedDouglas J. HulseJerry Ruddle · 1 companies · 1 sharedJerry RuddleJohn Ruddle · 1 companies · 1 sharedJohn RuddleJohn Toedtman · 1 companies · 1 sharedJohn ToedtmanMark J. Goran · 1 companies · 1 sharedMark J. GoranRichard F. Worthen · 1 companies · 1 sharedRichard F. WorthenTurnpoint Medical Devices, Inc. · $9.6M raisedTurnpoint Medical Dev…Joerge KlaubeJK
Joerge Klaube Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Joerge Klaube on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Joerg Klaube13
George Boyajian13
Joerg H. Klaube12
Christopher York12
Jerry C. Ruddle12
John Toedtman11
Jerry Ruddle11
John Ruddle11
Mark J. Goran11
Christopher J. York11
Richard F. Worthen11
Douglas C. Hulse11
Douglas Hulse11
Douglas J. Hulse11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.